Natixis Advisors LLC Has $1.17 Million Position in Structure Therapeutics Inc. (NASDAQ:GPCR)

Natixis Advisors LLC lifted its position in shares of Structure Therapeutics Inc. (NASDAQ:GPCR) by 40.4% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 26,675 shares of the company’s stock after acquiring an additional 7,670 shares during the period. Natixis Advisors LLC’s holdings in Structure Therapeutics were worth $1,171,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also made changes to their positions in the company. Sandia Investment Management LP bought a new stake in Structure Therapeutics during the second quarter worth $39,000. Assetmark Inc. raised its holdings in shares of Structure Therapeutics by 120.0% during the 3rd quarter. Assetmark Inc. now owns 1,318 shares of the company’s stock worth $58,000 after buying an additional 719 shares in the last quarter. Quarry LP bought a new stake in shares of Structure Therapeutics during the 2nd quarter worth $79,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in Structure Therapeutics by 60.1% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company’s stock valued at $158,000 after buying an additional 1,420 shares in the last quarter. Finally, Dearborn Partners LLC bought a new position in Structure Therapeutics in the third quarter valued at about $202,000. Institutional investors and hedge funds own 91.78% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on GPCR. Morgan Stanley initiated coverage on shares of Structure Therapeutics in a report on Monday, September 23rd. They set an “overweight” rating and a $118.00 price target on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $65.00 target price on shares of Structure Therapeutics in a research note on Monday, September 23rd. Finally, JMP Securities lowered their price target on shares of Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating for the company in a report on Friday, August 9th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $86.80.

Structure Therapeutics Stock Down 0.8 %

Shares of NASDAQ:GPCR opened at $33.74 on Wednesday. The firm has a market cap of $1.93 billion, a P/E ratio of -45.59 and a beta of -3.23. Structure Therapeutics Inc. has a 12-month low of $26.61 and a 12-month high of $66.38. The business has a fifty day simple moving average of $38.58 and a 200 day simple moving average of $39.50.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.